Marrow transplantation for stable-phase chronic granulocytic leukemia

James Olen Armitage, Lynell Warren Klassen, S. R. Patil, J. W. Kugler, R. D. Gingrich, G. B. Ahmann, M. A. Fyfe, H. H. Tewfik

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Ten patients with chronic granulocytic leukemia in the stable phase underwent marrow transplantation from HLA-identical siblings (nine cases) or an identical twin (one case) following preparation with cytarabine, cyclophosphamide, and total body irradiation. Marrow cytogenetics on all patients prior to transplantation revealed the Philadelphia chromosome without other evidence of aneuploidy. The immediate posttransplant course was in most cases relatively uncomplicated with only two serious infections and one death. All patients recovered with cytogenetically normal marrow and leukemia has recurred only in the syngeneic transplant recipient. At present, nine patients are surviving from 358 to 961 days (median 597 days) after bone marrow transplantation. Bone marrow transplantation is capable of eliminating the abnormal clone of myeloid cells in patients with stable-phase chronic granulocytic leukemia and can be performed relatively safely in this 'healthy' group of patients.

Original languageEnglish (US)
Pages (from-to)717-719
Number of pages3
JournalExperimental Hematology
Volume12
Issue number9
StatePublished - Dec 6 1984

Fingerprint

Leukemia, Myeloid, Chronic Phase
Transplantation
Bone Marrow
Bone Marrow Transplantation
Philadelphia Chromosome
Monozygotic Twins
Whole-Body Irradiation
Cytarabine
Aneuploidy
Myeloid Cells
Cytogenetics
Cyclophosphamide
Siblings
Leukemia
Clone Cells
Infection

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

Cite this

Armitage, J. O., Klassen, L. W., Patil, S. R., Kugler, J. W., Gingrich, R. D., Ahmann, G. B., ... Tewfik, H. H. (1984). Marrow transplantation for stable-phase chronic granulocytic leukemia. Experimental Hematology, 12(9), 717-719.

Marrow transplantation for stable-phase chronic granulocytic leukemia. / Armitage, James Olen; Klassen, Lynell Warren; Patil, S. R.; Kugler, J. W.; Gingrich, R. D.; Ahmann, G. B.; Fyfe, M. A.; Tewfik, H. H.

In: Experimental Hematology, Vol. 12, No. 9, 06.12.1984, p. 717-719.

Research output: Contribution to journalArticle

Armitage, JO, Klassen, LW, Patil, SR, Kugler, JW, Gingrich, RD, Ahmann, GB, Fyfe, MA & Tewfik, HH 1984, 'Marrow transplantation for stable-phase chronic granulocytic leukemia', Experimental Hematology, vol. 12, no. 9, pp. 717-719.
Armitage JO, Klassen LW, Patil SR, Kugler JW, Gingrich RD, Ahmann GB et al. Marrow transplantation for stable-phase chronic granulocytic leukemia. Experimental Hematology. 1984 Dec 6;12(9):717-719.
Armitage, James Olen ; Klassen, Lynell Warren ; Patil, S. R. ; Kugler, J. W. ; Gingrich, R. D. ; Ahmann, G. B. ; Fyfe, M. A. ; Tewfik, H. H. / Marrow transplantation for stable-phase chronic granulocytic leukemia. In: Experimental Hematology. 1984 ; Vol. 12, No. 9. pp. 717-719.
@article{3de9132c1e8c4493a446efe0ca514cb5,
title = "Marrow transplantation for stable-phase chronic granulocytic leukemia",
abstract = "Ten patients with chronic granulocytic leukemia in the stable phase underwent marrow transplantation from HLA-identical siblings (nine cases) or an identical twin (one case) following preparation with cytarabine, cyclophosphamide, and total body irradiation. Marrow cytogenetics on all patients prior to transplantation revealed the Philadelphia chromosome without other evidence of aneuploidy. The immediate posttransplant course was in most cases relatively uncomplicated with only two serious infections and one death. All patients recovered with cytogenetically normal marrow and leukemia has recurred only in the syngeneic transplant recipient. At present, nine patients are surviving from 358 to 961 days (median 597 days) after bone marrow transplantation. Bone marrow transplantation is capable of eliminating the abnormal clone of myeloid cells in patients with stable-phase chronic granulocytic leukemia and can be performed relatively safely in this 'healthy' group of patients.",
author = "Armitage, {James Olen} and Klassen, {Lynell Warren} and Patil, {S. R.} and Kugler, {J. W.} and Gingrich, {R. D.} and Ahmann, {G. B.} and Fyfe, {M. A.} and Tewfik, {H. H.}",
year = "1984",
month = "12",
day = "6",
language = "English (US)",
volume = "12",
pages = "717--719",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Marrow transplantation for stable-phase chronic granulocytic leukemia

AU - Armitage, James Olen

AU - Klassen, Lynell Warren

AU - Patil, S. R.

AU - Kugler, J. W.

AU - Gingrich, R. D.

AU - Ahmann, G. B.

AU - Fyfe, M. A.

AU - Tewfik, H. H.

PY - 1984/12/6

Y1 - 1984/12/6

N2 - Ten patients with chronic granulocytic leukemia in the stable phase underwent marrow transplantation from HLA-identical siblings (nine cases) or an identical twin (one case) following preparation with cytarabine, cyclophosphamide, and total body irradiation. Marrow cytogenetics on all patients prior to transplantation revealed the Philadelphia chromosome without other evidence of aneuploidy. The immediate posttransplant course was in most cases relatively uncomplicated with only two serious infections and one death. All patients recovered with cytogenetically normal marrow and leukemia has recurred only in the syngeneic transplant recipient. At present, nine patients are surviving from 358 to 961 days (median 597 days) after bone marrow transplantation. Bone marrow transplantation is capable of eliminating the abnormal clone of myeloid cells in patients with stable-phase chronic granulocytic leukemia and can be performed relatively safely in this 'healthy' group of patients.

AB - Ten patients with chronic granulocytic leukemia in the stable phase underwent marrow transplantation from HLA-identical siblings (nine cases) or an identical twin (one case) following preparation with cytarabine, cyclophosphamide, and total body irradiation. Marrow cytogenetics on all patients prior to transplantation revealed the Philadelphia chromosome without other evidence of aneuploidy. The immediate posttransplant course was in most cases relatively uncomplicated with only two serious infections and one death. All patients recovered with cytogenetically normal marrow and leukemia has recurred only in the syngeneic transplant recipient. At present, nine patients are surviving from 358 to 961 days (median 597 days) after bone marrow transplantation. Bone marrow transplantation is capable of eliminating the abnormal clone of myeloid cells in patients with stable-phase chronic granulocytic leukemia and can be performed relatively safely in this 'healthy' group of patients.

UR - http://www.scopus.com/inward/record.url?scp=0021172868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021172868&partnerID=8YFLogxK

M3 - Article

C2 - 6386509

AN - SCOPUS:0021172868

VL - 12

SP - 717

EP - 719

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 9

ER -